TYK2 Inhibition in Paradoxical Psoriasis

NCT06281106 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

TERMINATED

Status

2

Enrollment

OTHER

Sponsor class

Stopped External research funds were canceled, so study could unforunately not be continued

Conditions

Psoriasis

Interventions

DRUG: Deucravacitinib

Sponsor

Prof Curdin Conrad

Collaborators

[object Object]